home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Zymeworks Inc. - Common Stock (NQ:ZYME)

22.72 -0.60 (-2.57%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Zymeworks Inc. - Common Stock

< Previous 1 2 3 4 Next >

Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year ↗

Today 13:13 EST

This clinical-stage biotech develops targeted cancer therapies, leveraging bispecific antibodies and strategic industry partnerships.

Via The Motley Fool

Topics Regulatory Compliance

Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026

February 12, 2026

From Zymeworks Inc.

Via GlobeNewswire

Zymeworks Announces Participation in Upcoming Investor Conferences

January 27, 2026

From Zymeworks Inc.

Via GlobeNewswire

ZYMEWORKS INC (NASDAQ:ZYME) Fits the Minervini Trend Template with High Growth Momentum ↗

January 01, 2026

Via Chartmill

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy

January 12, 2026

From Zymeworks Inc.

Via GlobeNewswire

Zymeworks Outlines Strategic Priorities and Outlook for 2026

January 11, 2026

From Zymeworks Inc.

Via GlobeNewswire

Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit

January 06, 2026

From Zymeworks Inc.

Via GlobeNewswire

Which stocks are moving after the closing bell on Tuesday? ↗

December 02, 2025

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

Via Chartmill

Zymeworks Announces Participation in Upcoming Conferences

December 02, 2025

From Zymeworks Inc.

Via GlobeNewswire

Zymeworks Announces Participation in Upcoming Investor Conferences

November 24, 2025

From Zymeworks Inc.

Via GlobeNewswire

Zymeworks Stock Sees Surge In Retail Chatter After Royalty Pivot, Cancer Trial Win Sparks Target Price Hikes ↗

November 24, 2025

Strong new Phase 3 Ziihera data boosted confidence in upcoming regulatory milestones.

Via Stocktwits

Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033

November 18, 2025

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:NTLA),(NASDAQ:ZYME),(NYSE:ANVS) EQNX::TICKER_END

Via FinancialNewsMedia

Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033

November 18, 2025

From MarketNewsUpdates.com

Via GlobeNewswire

Alphabet To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

November 18, 2025

Via Benzinga

Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer

November 18, 2025

From Zymeworks Inc.

Via GlobeNewswire

Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets

November 18, 2025

From Zymeworks Inc.

Via GlobeNewswire

Let's take a look at the stocks that are in motion in today's session. ↗

November 17, 2025

Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans ↗

November 17, 2025

Zymeworks rises after Ziihera shows significant PFS and OS benefits in a Phase 3 trial, supporting plans for regulatory filings and guideline submissions.

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

November 17, 2025

Via Benzinga

Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday ↗

November 17, 2025

Via Benzinga

The market is filled with gapping stocks in Monday's session. ↗

November 17, 2025

In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.

Via Chartmill

Mixed Signals Point to Cautious Open for U.S. Markets as Tech Shines Amidst Economic Data Delays

November 17, 2025

U.S. equity futures are signaling a mixed but largely cautious start to the trading day on November 17, 2025, with technology stocks once again taking the lead, while broader indices like the Dow Jones...

Via MarketMinute

Topics Artificial Intelligence Economy Electric Vehicles

Jazz, Zymeworks Catapult On Their 'Sweeping Success' In Gastric Cancer ↗

November 17, 2025

Shares of Jazz Pharmaceuticals and Zymeworks catapulted Monday on positive test results for a gastric cancer drug.

Via Investor's Business Daily

These stocks are moving in today's pre-market session ↗

November 17, 2025

Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 17, 2025

Via Benzinga

Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

November 17, 2025

From Zymeworks Inc.

Via GlobeNewswire

Zymeworks Inc (NASDAQ:ZYME) Shows Strong Technical and Fundamental Momentum ↗

November 11, 2025

Discover how Zymeworks (ZYME) combines strong technical trends with accelerating earnings and sales growth, making it a top high-growth stock candidate.

Via Chartmill

Zymeworks Inc (NASDAQ:ZYME) Reports Mixed Q3 2025 Results with Narrower Loss but Revenue Miss ↗

November 06, 2025

Zymeworks Q3 2025: Narrower-than-expected loss and strong cash position, though revenue missed estimates. Clinical pipeline advances with promising data.

Via Chartmill

Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results

November 06, 2025

From Zymeworks Inc.

Via GlobeNewswire

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com